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Background: The consequences of opioid relapse among patients being treated with opioid substitution treatment
(OST) are serious and can result in abnormal cardiovascular function, overdose, and mortality. Chronic pain is a major risk
factor for opioid relapse within the addiction treatment setting. There exist a number of opioid maintenance therapies
including methadone, buprenorphine, naltrexone, and levomethadyl acetate (LAAM), of which the mediating effects of
pain on treatment attrition, substance use behavior, and social functioning may differ across therapies. We aim to 1)
evaluate the impact of pain on the treatment outcomes of addiction patients being managed with OST and 2) identify
the most recently published opioid maintenance treatment guidelines from the United States, Canada, and the UK to
determine how the evidence is being translated into clinical practice.
Methods/design: The authors will search Medline, EMBASE, PubMed, PsycINFO, Web of Science, Cochrane Database of
Systematic Reviews, ProQuest Dissertations and theses Database, Cochrane Central Register of Controlled Trials (CENTRAL),
World Health Organization International Clinical Trials Registry Platform Search Portal, and the National Institutes for Health
Clinical Trials Registry. We will search www.guidelines.gov and the National Institute for Care and Excellence (NICE)
databases to identify the most recently published OST guidelines. All screening and data extraction will be completed in
duplicate. Provided the data are suitable, we will perform a multiple treatment comparison using Bayesian meta-analytic
methods to produce summary statistics estimating the effect of chronic pain on all OSTs. Our primary outcome is
substance use behavior, which includes opioid and non-opioid substance use. We will also evaluate secondary endpoints
such as treatment retention, general physical health, intervention adherence, personal and social functioning, as well as
psychiatric symptoms.
Discussion: This review will capture the experience of treatment outcomes for a sub-population of opioid addiction
patients and provide an opportunity to distinguish the best quality guidelines for OST. If chronic pain truly does result
in negative consequences for opioid addiction patients, it is important we identify which OSTs are most appropriate for
chronic pain patients as well as ensure the treatment guidelines incorporate this information.
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Chronic non-cancer pain is a serious comorbidity impact-
ing the lives of over 95 million people, an estimated 30.7%
of the US population [1]. Chronic pain is defined as pain
lasting longer than 3 months or past the standard time for
tissue to heal [2]. Front-line treatments include the pre-
scription of long-acting opioids, although there is minimal
evidence to suggest that opioids provide any long-term re-
lief for chronic pain [3]. Trends in current prescribing
practice suggest that the rise in prescription opioid use [4]
has been paralleled by a concerning increase in opioid-
related deaths, addiction, and medication diversion [5-9].
Opioids are highly liable for misuse, which is evident from
the reported incidence of addiction, ranging from 3.2% to
27% among the chronic pain population [10].
While methadone is employed in the management of
chronic pain, its most common use is in the treatment of
opioid addiction [11], known formally as methadone
maintenance treatment (MMT). Under the supervision of
addiction specialists, methadone (a synthetic opioid) is
prescribed to alleviate the symptoms of withdrawal and
prevent relapse [11]. Within the addiction population be-
ing treated with methadone, chronic non-cancer pain is
the most commonly reported comorbidity, with an esti-
mated prevalence ranging from 37% to 55.3% [12-14].
The intersection between pain management, opioid
dependence, and addictive behavior inflates the chal-
lenges of treating both addiction and chronic pain. In
addition to psychiatric disturbance and inadequate social
support, chronic pain is known to be one of the greatest
risk factors for opioid relapse within the methadone setting
[15,16]. These effects are argued to be the result of opioid-
induced hyperalgesia, characterized as a status of height-
ened nociceptive sensitization caused by opioid exposure
[17]. This effect has been demonstrated repeatedly, whereby
patients with non-cancer chronic pain taking methadone
showed increased hyperalgesic response (assessed by cold
presser test but not stimulus) in comparison to their
placebo-matched controls [17,18].
The risk for abnormal cardiovascular function [19,20],
overdose [21,22], and mortality [21] is highest among pa-
tients abusing opioids in combination with MMT. Classify-
ing chronic pain as a risk factor for continued opioid abuse
[12,15,16,23] calls to question which addiction treatment is
most appropriate for patients with comorbid pain. There
exist a number of opioid maintenance therapies including
methadone, buprenorphine, naltrexone, and levomethadyl
acetate (LAAM), of which the mediating effects of pain on
treatment attrition, substance use behavior, and social
functioning may differ across therapies.
Is chronic pain an important mediating factor when
evaluating patient response to opioid addiction treat-
ment? Which opioid maintenance therapy is best for im-
proving physical, psychiatric, and substance use behavioroutcomes in patients with opioid addiction and chronic
pain? We aim to evaluate these questions using evidence
gathered from all studies evaluating chronic pain in the
opioid addiction patient population. The lack of current
summary of evidence evaluating the mediating effects of
pain suggests that our current effort to combine the evi-
dence will serve to 1) distinguish the best therapy for
opioid addiction patients with comorbid pain and 2) en-
able clinicians to tailor treatments based on an import-
ant and highly prevalent risk factor.
Objectives
We aim to 1) evaluate the impact of comorbid chronic
non-cancer pain on all opioid addiction treatment out-
comes reported in the literature including treatment re-
tention, illicit substance-use behavior, as well as physical
and psychiatric symptoms, 2) determine how different
opioid maintenance treatments compare in their effect-
iveness for patients with comorbid chronic non-cancer
pain, 3) provided the data are suitable, combine the evi-
dence from direct and indirect comparisons using net-
work meta-analysis, and 4) identify the most recently
published opioid maintenance treatment guidelines from
the United States, Canada, and the UK to determine
how the evidence is being translated into clinical prac-
tice for addiction management.
Research questions
1.1Among patients with opioid addiction being treated
with (or randomized to) opioid substitution
treatment (OST): 1) does chronic non-cancer pain
interfere with the effect of OST, and 2) which OST
is best for improving treatment response for patients
with comorbid chronic non-cancer pain? We will
evaluate response across multiple outcome domains
including: substance use behavior, physical health,
psychiatric symptoms, as well as personal and social
functioning.
1.2Do the most recently published United States,
Canadian, and United Kingdom OST clinical
practice guidelines capture and properly translate




Inclusion and exclusion criteria
To be included in this review, the study must evaluate
the impact of chronic pain on patient’s response to opi-
oid addiction treatment. The study must have provided
a comparison of response to treatment outcomes (for
example, continued opioid abuse, general physical
health) between patients with and without chronic pain.
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on an OST for opioid addiction. We will not place any
restrictions on the types of OST or measurement of
chronic pain. All study designs will be accepted into this
review, (that is, randomized controlled trials, observa-
tional studies, or qualitative studies). No restrictions
were placed on socioeconomic, geographic, or ethnic
backgrounds of participants for this review.
To be eligible for inclusion, all studies must be pri-
mary (original research in patients with pain, no second-
ary reporting), completed (no interim analyses will be
allowed in this review), and performed in a human
population.
Outcome measures
The primary outcome in this review is illicit opioid use,
which can be measured in various ways including urine
toxicology screening or self-report. We anticipate many
definitions and measurements of opioid use. For ex-
ample, some studies measure opioid use behavior as the
number of days of opioid use in the last month, while
others report the mean number of positive opioid urine
screens or days until opioid relapse. We will accept any
definition or measurement of illicit opioid use, provided
the study performs an analysis comparing opioid use be-
havior based on patients’ chronic pain status. We will
also abstract data on all other efficacy end-points includ-
ing non-opioid substance abuse, general physical health,
psychiatric symptoms, personal and social functioning,
intervention adherence (for example, treatment reten-
tion, dropout rate), resource utilization (for example,
hospital admissions) as well as treatment preference.
However, short-term outcomes (initial dosing, initial re-
sponse in a period of <3 weeks, or early detoxification
response) will not be evaluated.
Data sources and search strategy
We will perform an electronic search using the Medline,
EMBASE, PubMed, PsycINFO, Web of Science, Cochrane
Database of Systematic Reviews, ProQuest Dissertations and
theses Database, Cochrane Central Register of Controlled
Trials (CENTRAL), World Health Organization Inter-
national Clinical Trials Registry Platform Search Portal,
and the National Institutes for Health Clinical Trials
Registry. In addition, the reference lists of all Cochrane
reviews addressing this topic will be reviewed. We will
use the Cochrane reviews to validate our own searches
of databases and ensure that we have captured the rele-
vant articles in our field. This supplementary search will
be applied to Cochrane reviews since they are consid-
ered the gold standard in systematic reviews.
We will use a comprehensive search strategy tailored for
each database. Please refer to Table 1 for an outline of the
search strategy. We consulted a McMaster UniversityFaculty of Health Science librarian as needed throughout
the design and investigation phases of the study. The
search will be restricted to human studies. Our search will
not be restricted to the published literature. We acknow-
ledge that studies in the unpublished literature may not be
subject to the same scrutiny as the investigations published
in peer-reviewed journals. However, the unpublished litera-
ture meeting the inclusion criteria will still be subject to
the same rigorous risk of bias assessment as all studies in-
cluded in this review. To ascertain the gray literature, we
will perform a search using the ProQuest Dissertations and
theses Database. The title, abstract, and full-text screening
will be performed in duplicate by two independent re-
viewers (Dennis, B and Bawor, M).
Selection of studies
Two independent reviewers will screen titles and ab-
stracts and potentially eligible full-text articles using pre-
defined inclusion criteria. Any disagreements or
variability between reviewers will be resolved by discus-
sion. If discussion does not lead to a resolution, a third
author (Samaan, Z) will be consulted and have the final
judgment over the disputed article. We will calculate
and report the kappa statistic for each stage (title, ab-
stract, full-text) of screening to display the level of agree-
ment between reviewers.
This review will be reported in accordance with the
PRISMA guidelines [24]. The review will include a flow
diagram (Figure 1) of the article screening process.
Data abstraction
The two authors (BD and MB) will independently ex-
tract data from the studies using a pre-established data
extraction form (DEF), which is available upon request.
All study information will be recorded onto the DEF and
later entered onto an electronic Microsoft Excel sheet.
The independent reviewers will extract all eligible stud-
ies in duplicate. Similar to the methods for disagreement
resolution during the title and abstract screening, the in-
dependent reviewers will first discuss the disagreements
they have during the data abstraction. When discussion
does not lead to a resolution, a third reviewer (Samaan, Z)
will provide the final decision over the disagreement.
Information extracted during the data abstraction will in-
clude author, date of publication, journal of publication,
number of study participants, type of population (clinical,
incarcerated, pregnant), eligibility criteria, OST(s), OST
dose (by chronic pain status), definition of chronic pain,
identification of primary outcome, definition of response
outcome(s), measurement of chronic pain, measurement
of response outcome(s), percentage/number of participants
with chronic pain, statistical analysis performed, study find-
ings, overall statistical findings, factors associated with
treatment response (if reported), and author’s conclusions.
Table 1 Electronic search strategy for the identification of relevant studies across multiple databases
Databases Search strategies
MEDLINE Search = ______ 1. substance related disorders.mp. or Substance-Related Disorders/
2. opioid related disorders.mp. or Opioid-Related Disorders/
3. Opioid-Related Disorders/or Methadone/or Analgesics, Opioid/or Heroin Dependence/
4. 1 or 2 or 3
5. methadone.mp. or Methadone/
6. Opiate Substitution Treatment/or Naloxone/ or Buprenorphine/or Opioid-Related Disorders/
or Narcotic Antagonists/
7. buprenorphine.mp. or Buprenorphine/
8. naltrexone.mp. or Naltrexone/
9. Substance Abuse Treatment Centers/or Heroin/or Heroin Dependence/or Opioid-Related
Disorders/or Randomized Controlled Trials as Topic/or Methadone/
10. opioid substitution treatment.mp. or Opiate Substitution Treatment/
11. Buprenorphine/or Analgesics, Opioid/or Opioid-Related Disorders/or Methadone/or
Heroin Dependence/
12. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
13. chronic pain.mp. or Chronic Pain/
14. 4 and 13 and 4
15. limit 15 to humans
Web of Science Search = ______ 1. Topic = (“methadone” OR “methadone maintenance therapy” OR “naltrexone” OR
“suboxone” OR “buprenorphine” OR “heroin assisted treatment”)
2. Topic = (“opioid dependence” or “addiction”)
1. Topic = (“chronic pain” OR “pain” OR “opioid induced hyperalgesia”)
2. 1 AND 2 AND 3
EMBASE = _____ 1. methadone treatment/or methadone.mp. or methadone/or methadone plus
naloxone/
2. heroin dependence/or maintenance therapy/or methadone/or opiate addiction/or
diamorphine/or methadone treatment/
3. buprenorphine/or buprenorphine.mp.
4. naltrexone.mp. or morphine sulfate plus naltrexone/or naltrexone/
5. opioid substitution treatment.mp. or opiate substitution treatment/
6. methadone/ or diamorphine/or heroin dependence/
7. levomethadyl acetate.mp. or levacetylmethadol/
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. substance related disorder.mp. or addiction/
10. naltrexone/ or buprenorphine/or opioid addiction.mp. or methadone/
11. 9 or 10
12. chronic pain.mp. or chronic pain/
13. 8 and 11 and 12
14. limit 13 to human
PsychINFO Search = _____ 1. exp Drug Therapy/or exp Methadone Maintenance/or exp Heroin Addiction/
2. exp Methadone/or exp Naloxone/or exp Drug Therapy/or exp Drug Dependency/or
buprenorphine.mp.
3. naltrexone.mp. or exp Naltrexone/
4. exp Heroin Addiction/or exp Drug Rehabilitation/or exp Drug Dependency/or exp
Clinical Trials/
5. exp Drug Therapy/or exp Methadone Maintenance/
6. 1 or 2 or 3 or 4 or 5
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Table 1 Electronic search strategy for the identification of relevant studies across multiple databases (Continued)
7. exp Drug Abuse/or substance related disorder.mp. or exp Drug Dependency/
8. substance abuse.mp. or exp Drug Abuse/
9. 7 or 8
10. chronic pain.mp. or exp Chronic Pain/
11. 6 and 9 and 10
Cochrane Library: Cochrane Review and Cochrane Central
Register of Controlled Trials = _____
Search title, abstract, keywords:
1. “methadone” OR “naltrexone” OR “buprenorphine” OR “opioid substitution treatment”
OR “levo-methadyl acetate” OR “heroin assisted treatment” OR “heroin substitution
treatment”
2. “substance abuse disorder” OR “opioid abuse” OR “substance-related disorder” OR
“opioid addiction”
3. “chronic Pain” OR “pain” OR “hyperalgesia” OR “neuropathic pain”
Clinical Trials Registry through National Institutes for
Health = _____
“methadone” OR “suboxone” OR “Buprenorphine” OR “substitute opioid therapy” OR
“naltrexone” OR “heroin assisted treatment” OR “heroin adjustment therapy” AND “opioid
addiction” AND “chronic pain”, with additional criteria including: Completed studies, all
trials had to be listed as Phase 3, 4
World Health Organization International Clinical Trials
Registry Platform Search Portal = _________
“‘opioid addiction’ OR ‘opioid substitution treatment’ OR ‘opioid maintenance treatment’
OR ‘methadone maintenance treatment’” AND “chronic pain”
ProQuest Dissertations and theses Database = _____ “opioid addiction” OR “opioid dependence” AND “pain” OR “Chronic Pain”
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Two independent reviewers will assess the methodo-
logical quality of the studies in duplicate using a modi-
fied Newcastle Ottawa scale for case-control and cohort
studies [25], the NIH National Heart, Lung, and Blood
Institute: Quality Assessment Tool for Cross-Sectional
Studies [26], and the Cochrane Risk of Bias Tool [27] for
randomized controlled trials. As mentioned above, any
discrepancies between the independent reviewers will
first be resolved by discussion; if discussion does not lead
to an adequate solution, a third reviewer (Samaan, Z) will
be brought in with the responsibility of resolving the
dispute.
All summary estimates obtained from meta-analysis will be
subject to evaluation using the Grading of Recommendations
Assessment, Development and Evaluation (GRADE)
guidelines [28]. Provided the data are appropriate, sum-
mary statistics derived for direct and indirect estimates
using NMA will also be subject to assessment using the
GRADE framework [29].
Statistical analysis methods
The results of this systematic review will be reported in
a narrative and where possible, a combined statistical
manner. Agreement levels between the independent re-
viewers will be measured using the kappa statistic. Pro-
vided there is little heterogeneity between studies, we
plan to conduct a meta-analysis to derive a summary
statistic representing the combined statistical result of
multiple studies across our primary outcome (illicitopioid use behavior) and secondary efficacy end-points.
As described previously [30], the lack of direct compari-
sons reported in the literature is a common problem
when combining the evidence from studies evaluating
OSTs. The majority of studies evaluate new therapies in
direct comparison to methadone or placebo, leaving us
to question the comparative effectiveness compared to
other OSTs. To circumvent this problem, we are propos-
ing using network meta-analysis (NMA) to provide the
pooled effect estimates of chronic pain mediating effects
on the primary outcome (illicit opioid use behavior) for
all OSTs.
Research methodologists highly caution against the
pooling of studies with fundamentally different designs,
[31,32] largely because of imbalanced susceptibility to
selection bias non-randomized studies face [31]. Thus,
we will combine the results of randomized and non-
randomized studies in separate meta-analyses.
Direct comparisons
We will perform a meta-analysis to pool results for our pri-
mary outcome as well as all secondary efficacy end-points.
Findings abstracted from direct comparisons will be pooled
together using a random-effect meta-analysis with Knapp-
Hartung (KH) estimator [33]. All analyses will be per-
formed using the metafor and rmeta packages in R [34].
Dichotomous outcome(s) will be combined into a
pooled odds ratio, where continuous outcomes (for ex-
ample, mean number of positive opioid urine screens
evaluated by chronic pain status) will be pooled using
Figure 1 Flow diagram of article screening process.
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will be weighted using the inverse of the variance.
Results from studies deemed eligible for inclusion into
the meta-analysis will be presented in a forest plot, with
the associated 95% confidence intervals presented. We
will calculate and report the inconsistency index (I2)statistics and P values as the measure of heterogeneity in
the results of the studies and whether the actual ob-
served difference can be attributable to chance alone
[35]. We will interpret the I2 statistic using the thresh-
olds set forth by the Cochrane Collaboration, these in-
clude I2 of 0% to 40% (might not be important), 30% to
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heterogeneity), and 75% to 100% (considerable hetero-
geneity) [31]. The Egger’s test will be used to assess for
publication bias.
We anticipate a study’s scoring on methodological
quality assessment as well as differences in measurement
selection (for example, urine toxicology screening versus
self-report) to be important factors accounting for hetero-
geneity between studies. The methodological quality of in-
dividual studies will be captured using the Cochrane Risk
of Bias tool, Newcastle Ottawa Scale, and the NIH National
Heart, Lung, and Blood Institute: Quality Assessment Tool
for Observational Cohort and Cross-Sectional Studies.
Subgroup analyses will stratify on the basis of the study’s
performance on the risk of bias assessment. We will stratify
our analyses on the basis of Cochrane risk of bias re-
sponses, whereby studies will be characterized has having
an overall ‘high risk of bias’ if at least one domain on the
Cochrane risk of bias tool is rated as high risk. Thus, re-
sults of any study with ≥1 ‘high risk of bias’ rating across
domains will be considered at risk for confounding. For
observational studies, we will need to address risk of bias
according to the appropriate assessment tools, thus we will
not be able to use Cochrane risk of bias across all studies.
For cohort and case-control studies, any study with zero
stars in ≥1 section will be considered high risk of bias
based on the Newcastle Ottawa Scale. According to the
Newcastle Ottawa Scale, receiving stars indicates a lower
risk of bias. The lack of stars in any section indicates the
study has not addressed a possible source of confounding.
For cross-sectional studies rated with the NIH tool, any
study receiving a ‘fair’ or overall ‘poor’ quality rating will be
classified as high risk of bias and included for subgroup
analysis. We anticipate the studies with improper adjust-
ment for important confounding variables to have high
susceptibility for confounded treatment effects.
We will also stratify our meta-analyses based on out-
come measurement. A clear example of how measure-
ment can influence the study results is noted with the
measurement of opioid use, where some studies use urine
toxicology screening to determine concomitant opioid
abuse and other studies use self-report. Self-report is sus-
ceptible to social desirability bias, where some patients
may be reluctant to report continued opioid abuse in an
effort to maintain a positive standing with physicians and
clinical staff. Thus, quality of measurement can contribute
to large difference in the study findings.
Acknowledging the impact of publication status as a po-
tential source of bias, we will perform sensitivity analysis
to determine whether a study’s publication status impacts
the observed effect estimates. Studies in the gray literature
are not subject to the same level of scrutiny as those in
peer-reviewed journals. The peer review process leads to
the identification of potential sources of confounding andallows authors to re-perform their analyses by properly
adjusting for newly identified sources of error. Thus, some
of the unpublished literature may present different treat-
ment effects simply due to the lack of external evaluation.
We will evaluate this potential concern by performing an
additional sensitivity analysis, stratifying our meta-analyses
by the articles publication status.
Combining direct and indirect evidence: the network
meta-analysis
Provided the data are suitable for NMA, we propose
building a Bayesian hierarchical model using maximum
likelihood estimation to derive summary statistics for
binary outcomes. This model will introduce a random
effect representing the variation in effect estimates
resulting from the comparison itself. Any variation in
the random effect will be considered ‘inconsistency’ [36].
This method allows for treatment heterogeneity, sam-
pling variability, and inconsistency [36] while also apply-
ing maximum likelihood estimation [36].
Due to the fragility of the NMA, we propose selecting
the best evidence for inclusion into the model. Thus,
only evidence from randomized trials with ≥200 people
in the comparison will be selected for inclusion into the
NMA model. We set this sample size requirement to ad-
just for the high susceptibility of type I error in studies
evaluating multiple treatment outcomes.
We will use node splitting to identify inconsistency
[37,38], a method that identifies loops with large incon-
sistency. The inconsistency will be taken into consider-
ation during the interpretation of the results. We will
also use the deviance information criterion (DIC) to esti-
mate how parsimonious the data are [37].
Findings from the NMA will be presented using prob-
ability statements of treatment effects as well as a ranking
of these probabilities, which illustrates each interventions
probability of ranking first [39]. We will also graphically
display the probability ranks using the surface under the
cumulative ranking (SUCRA) line [39].
Methods for evaluating the clinical guidelines
To identify the most recently published North American
guidelines on opioid maintenance treatments, we will
search www.guidelines.gov. We will search using the
terms ‘opioid dependence, opioid addiction, and opioid
substitution treatment.’ We will also search the National
Institute for Health and Care Excellence (NICE) data-
base to identify the most recently published guidelines
used by the National Health Service in the UK. We will
use pilot-tested data abstraction forms to extract data
on: the recommendations made by each guideline, the
strength of the recommendation, the evidence cited by
the guideline for each recommendation, whether the
guideline developers interpreted any clinical subgroup
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the impact of pain on poor treatment response. We will
also quantitatively appraise the quality of the guidelines
using the Appraisal of Guidelines for Research & Evalu-
ation II (AGREE) Instrument, a validated tool used for
guideline assessment [40,41]. We will use this tool to as-
sess the transparency in the development of guideline
recommendations for chronic pain subpopulations.
However, the use of the AGREE II will be unjustified if
no formal recommendations are made for managing this
population.
Discussion
Understanding the impact of comorbid disorders on ad-
diction treatment outcomes is essential for enhancing
evidence-based practices within the field of mental
health and addiction. This investigation will focus on de-
termining the role that chronic non-cancer pain has on
the patient’s experience of opioid addiction treatment.
Acknowledging the complexity of comorbid pain man-
agement within the addiction treatment setting, we aim
to understand the extent to which chronic pain is related
to negative health outcomes including functional disabil-
ity, physical difficulty, and mental health problems such
as depression and anxiety in the context of opioid addic-
tion [10]. Determining the influence of chronic pain on
response to OST will require a detailed assessment
across several different patient important outcomes. This
review will capture the experience of treatment for a
substantive sub-population of opioid addiction patients.
If chronic pain truly does result in negative conse-
quences for opioid addiction patients, it is important
that we identify which OST is most appropriate for
chronic non-cancer pain patients. We will also identify
how current evidence is translated into practice by thor-
oughly reviewing international guidelines for OST. We
aim to address how addiction treatment guidelines
propose managing patients with comorbid pain. This ob-
jective provides an opportunity to distinguish the best
quality guidelines and ultimately identify future areas for
improvement.
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